229 related articles for article (PubMed ID: 16570285)
1. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.
van Oers JM; Adam C; Denzinger S; Stoehr R; Bertz S; Zaak D; Stief C; Hofstaedter F; Zwarthoff EC; van der Kwast TH; Knuechel R; Hartmann A
Int J Cancer; 2006 Sep; 119(5):1212-5. PubMed ID: 16570285
[TBL] [Abstract][Full Text] [Related]
2. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses.
Obermann EC; Junker K; Stoehr R; Dietmaier W; Zaak D; Schubert J; Hofstaedter F; Knuechel R; Hartmann A
J Pathol; 2003 Jan; 199(1):50-7. PubMed ID: 12474226
[TBL] [Abstract][Full Text] [Related]
3. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
4. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma.
Hartmann A; Moser K; Kriegmair M; Hofstetter A; Hofstaedter F; Knuechel R
Am J Pathol; 1999 Mar; 154(3):721-7. PubMed ID: 10079249
[TBL] [Abstract][Full Text] [Related]
5. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer.
Stoehr R; Zietz S; Burger M; Filbeck T; Denzinger S; Obermann EC; Hammerschmied C; Wieland WF; Knuechel R; Hartmann A
Eur Urol; 2005 Jan; 47(1):58-63. PubMed ID: 15582250
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
8. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
[TBL] [Abstract][Full Text] [Related]
10. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
11. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
[TBL] [Abstract][Full Text] [Related]
13. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
[TBL] [Abstract][Full Text] [Related]
16. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
17. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.
Zieger K; Marcussen N; Borre M; Ørntoft TF; Dyrskjøt L
Int J Cancer; 2009 Nov; 125(9):2095-103. PubMed ID: 19637316
[TBL] [Abstract][Full Text] [Related]
18. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer.
Chow NH; Cairns P; Eisenberger CF; Schoenberg MP; Taylor DC; Epstein JI; Sidransky D
Int J Cancer; 2000 Nov; 89(6):514-8. PubMed ID: 11102896
[TBL] [Abstract][Full Text] [Related]
19. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer.
Stoehr R; Wissmann C; Suzuki H; Knuechel R; Krieg RC; Klopocki E; Dahl E; Wild P; Blaszyk H; Sauter G; Simon R; Schmitt R; Zaak D; Hofstaedter F; Rosenthal A; Baylin SB; Pilarsky C; Hartmann A
Lab Invest; 2004 Apr; 84(4):465-78. PubMed ID: 14968126
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of FGFR3 mutations and chromosomal alterations in bladder cancer].
Junker K; van Oers JM; Zwarthoff EC; Kania I; Schubert J; Hartmann A
Verh Dtsch Ges Pathol; 2006; 90():151-8. PubMed ID: 17867592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
